Solid Biosciences (SLDB) Debt to Equity (2024 - 2026)

Solid Biosciences has disclosed Debt to Equity across 3 years of filings, most recently posting $0.01 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.01, down 45.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.01 (down 45.07% YoY), and the FY2025 annual result was $0.05, up 122.68% from the prior year.
• Debt to Equity came in at $0.01 for Q1 2026 at Solid Biosciences, down from $0.05 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.05 in Q4 2025 to a low of $0.01 in Q1 2026.
• The 3-year median for Debt to Equity is $0.02 (2025), against an average of $0.02.
• Across the five-year window, Debt to Equity jumped 122.68% in 2025 and sank 45.07% in 2026, its largest moves.
• Solid Biosciences' Debt to Equity stood at $0.02 in 2024, then surged by 122.68% to $0.05 in 2025, then slumped by 82.48% to $0.01 in 2026.
• The last three Debt to Equity figures came in at $0.01 (Q1 2026), $0.05 (Q4 2025), and $0.03 (Q3 2025), per Business Quant data.